Completed Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment NCT03059992 Conditions Allergic Bronchopulmonary Aspergillosis, Aspergillosis, Aspergillosis, Allergic Bronchopulmonary, +44 more Locations University of Alabama at Birmingham — Birmingham, Alabama, United States UC Davis Medical Center — Sacramento, California, United States University of California San Francisco — San Francisco, California, United States Emory University Hospital Midtown — Atlanta, Georgia, United States View all 37 locations View more locations Show fewer locations Loading locations... View Trial Details
